Sanford C. Bernstein set a €90.00 ($104.65) price objective on Bayer (FRA:BAYN) in a report issued on Monday morning, Borsen Zeitung reports. The firm currently has a buy rating on the healthcare company’s stock.
Other equities analysts also recently issued research reports about the stock. Deutsche Bank set a €70.00 ($81.40) target price on shares of Bayer and gave the stock a neutral rating in a research note on Thursday, October 31st. Morgan Stanley set a €86.00 ($100.00) target price on shares of Bayer and gave the stock a buy rating in a research note on Monday, January 6th. DZ Bank reiterated a neutral rating on shares of Bayer in a research note on Thursday, October 31st. Independent Research set a €61.00 ($70.93) target price on shares of Bayer and gave the stock a sell rating in a research note on Thursday, October 31st. Finally, Berenberg Bank set a €86.00 ($100.00) target price on shares of Bayer and gave the stock a buy rating in a research note on Tuesday, December 17th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and nine have given a buy rating to the company’s stock. The stock currently has an average rating of Hold and a consensus target price of €79.94 ($92.95).
Shares of BAYN stock opened at €74.90 ($87.09) on Monday. The firm has a fifty day moving average price of €71.61 and a 200 day moving average price of €66.01. Bayer has a 12 month low of €91.58 ($106.49) and a 12 month high of €123.82 ($143.98).
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.